| Website | vivoventures.com |
| Phone | (650) 688-0818 |
| info@vivoventures... | |
| Employees | |
| Founded | 1996 |
| Description | life-science investments |
| Total | $650M |
| BioAsia Investments, 5/07 | $275M |
| Vivo Ventures VII, 1/12 | $375M |
Vivo Ventures is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth fund into promising biotechnology and life science companies.
With over 90 years of scientific and operational expertise in biotechnology, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, arrange licensing agreements and strategic alliances, recruit key management personnel, and acquire new products and technology to accelerate growth. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
| Company | Date | Round | Size | Participants |
| Aclaris Therapeutics | 10/12 | Series A | $21M | 3 |
| Ceptaris Therapeutics | 6/12 | Series D | $10M | 6 |
| SentreHEART | 6/12 | Series C | $26M | 3 |
| AirXpanders | 1/12 | Series D | $10M | 4 |
| Medley Health | 11/11 | Series A | $20M | 3 |
| Rempex Pharmaceuticals | 11/11 | Series B | $67.5M | 5 |
| Yaupon Therapeutics | 8/11 | Series D | $14.4M | 4 |
| Revance Therapeutics | 6/11 | Venture Round | $45M | 7 |
| NextWave Pharmaceuticals | 1/11 | Series C | $45M | 7 |
| TRIA Beauty | 9/10 | Venture Round | $15.6M | 4 |
| Vicept Therapeutics | 6/10 | Series A | $16M | 3 |
| Neomend | 1/10 | Series D | $30M | 5 |
| Revance Therapeutics | 1/10 | Series D | $25M | 5 |
| Sagent Pharmaceuticals | 6/09 | Series A | $30M | 1 |
| Eiger BioPharmaceuticals | 2/09 | Series A | $7.1M | 2 |
| APT Pharmaceuticals | 9/08 | Series A | $32M | 7 |
| InteKrin | 8/08 | Series C | $18.5M | 7 |
| Carbylan BioSurgery | 11/07 | Series B | $20M | 3 |
| Transcept Pharmaceuticals | 3/07 | Series D | $40M | 8 |
| CAPNIA | 5/04 | Series B | $12M | 3 |
